Professor Wu Won Second Prize in the National Science and Technology Progress Award in 2016

On January 9, the official award ceremony for State Science and Technology Prizes was held in Beijing by the Central Committee of the Communist Party of China and the State Council. Secretary General Xi Jinping attended the ceremony and awarded the winner of the highest prize. Professor Wu Depei (Director of the Hematology Department of the First Affiliated Hospital of Soochow University and Director-elect of the Chinese Society of Hematology of Chinese Medical Association) accepted the prize in the Great Hall of the People in Beijing. The Innovation and Promotion of Key Diagnosis and Treatment Technology for Hematological Malignant Tumors, which is jointly completed by the First Affiliated Hospital of Soochow University, the Blood Diseases Hospital (Institute of Hematology) at Chinese Academy of Medical Sciences, and Soochow University, has won second prize in the National Science and Technology Progress Award.


Over the last 22 years, ten hematology experts and scholars, namely, Mr. Wu Depei, Mr. Xie Yongquan, Mr. Chen Suning, Mr. Xiao Zhijian, Mr. Chen Zixing, Ms. Qiu Huiying, Ms. Tang Xiaowen, Ms. Han Yue, Mr. Xu Yang, and Mr. Luan Changgeng, have carried out in-depth research over the pathogens of leukemia, regulated diagnosis and treatment of myelodysplastic syndromes (MDS), and key technologies for treatment of high-risk patients by transplanting hematopoietic stem cells, yielding a series of achievements. The achievements have been promoted to major A-level tertiary hospitals and grass-root hospitals nationwide, significantly improving the diagnosis and treatment of leukemia and MDS in China.


The research achievements for the last 22 years yielded by the Hematology Department of the First Affiliated Hospital of Soochow University originate from the lifetime research and accumulation of hematology experts and scholars in Suzhou, whose innovative technologies represent the advanced level in the diagnosis and treatment of hematological malignant tumors in China.


First scientific innovation: The Hospital has discovered a new genetic mechanism for leukemia, revealing the key pathogenic targets of leukemia in the central nervous system; and discovered two sub-types of leukemia, which are included to the WHO classification of the diagnostic criteria for leukemia.


Second scientific innovation: The Hospital has discovered a new subtype of chromosome of MDS and its genetic evolution mechanism; revealed the genetic abnormality and significance related to the morbidity of MDS; and established a diagnostic and treatment strategy of MDS and compiled the first guidelines to diagnose and treat MDS in China.


Third scientific innovation: The Hospital has established a dual transplant system of haplotype donor and third party umbilical cord blood; and a new therapy for curing relapse after treatment by infusing lymphocyte from the donor activated by interferon -α and post-transplantation comprehensive prevention and curing technology system for complications, significantly improving the efficiency of transplantation.